TCG Lifesciences today announced a strategic collaboration with ENDO Pharmaceuticals (Nasdaq: ENDP) to discover novel small molecule drug candidates for the treatment of pain. Working closely with ENDO scientists the collaboration will focus on an integrated approach involving medicinal chemistry, biology and animal pharmacology capabilities of Chembiotek. ENDO will have full ownership of the compounds developed under the collaboration with exclusive worldwide rights, and will fund all subsequent drug development and commercialization activities. ENDO will provide research funding and pay success based discovery milestones payments to TCG Lifesciences.
Ivan Gergel, MD, Endo EVP of research and development, stated: “We are excited to be working with TCG Lifesciences in our efforts to discover, develop and deliver the right kinds of treatment solutions to patients and providers. This collaboration is consistent with our strategy of building Endo’s pipeline using a virtual discovery approach, in conjunction with our in-licensing efforts.”
According to Mr. Swapan Bhattacharya, Managing Director, TCG Lifesciences, “This partnership with ENDO is a result of the skills, capabilities and scale of operations we have developed over the past few years at TCG Lifesciences and more specifically at Chembiotek. This also highlights TCG Lifesciences focus on developing special platform technologies, electrophysiology and specific animal models relevant to preclinical research in the area of pain. Our talented and dedicated team of scientists working in the area of medicinal chemistry, biology and animal pharmacology have made this possible.”
About TCG Lifesciences Limited
TCG Lifesciences Limited is a leading research services and informatics company with operations in India, Europe, Japan and the United States. It is part of The Chatterjee Group, a global investment conglomerate headquartered in New York. TCG Lifesciences Limited (“TCGLS”) collaborates to service the multi-disciplinary research efforts of global pharmaceutical and biotechnology companies through its 3 units Chembiotek (Discovery Research), Clininvent (Clinical Research Solutions) & LabVantage (Enterprise Informatics). It has trust based relationships with majority of the global pharmaceutical companies. The relationships span from specific solutions and sourcing services to integrated projects across multiple domains to complete translational research programs in the drug discovery and development space.PDF